Empliciti

Description

Empliciti (elotuzumab)

Background
Empliciti is a monoclonal antibody that specifically targets the SLAMF7 protein. Multiple myeloma is a cancer that forms in a type of white blood cell called plasma cells. SLAMF7 protein is expressed on both myeloma and natural killer cells. Empliciti exerts its anticancer effects by targeting the SLAMF7 protein on myeloma cells directly and by increasing interaction with natural killer cells to mediate the killing of myeloma cells. This drug is administered intravenously every week for the first two cycles and then every 2 weeks onward until disease progression or unacceptable toxicity (1).

Regulatory Status
FDA-approved indication: Empliciti is a SLAMF7-directed immunostimulatory antibody indicated in: (1)

1. combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies
2. combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor

Empliciti therapy may cause elevations in liver enzymes (aspartate transaminase/alanine transaminase [AST/ALT] greater than 3 times the upper limit, total bilirubin greater than 2 times the upper limit, and alkaline phosphatase less than 2 times the upper limit) consistent with
hepatotoxicity. Liver function should be monitored periodically and therapy stopped upon Grade 3 or higher elevation and continuation of therapy considered after return to baseline values (1).

Safety and effectiveness of Empliciti have not been established in pediatric patients (1).

Related Policies

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Empliciti may be considered medically necessary in patients 18 years of age or older for the treatment of multiple myeloma and if the conditions indicated below are met.

Empliciti is considered investigational in patients less than 18 years of age and for all other indications.

Prior-Approval Requirements

Age

18 years of age and older

Diagnosis

Patient must have the following:

Multiple myeloma (MM)

AND ALL of the following:

1. Patient has **ONE** of the following:
   a. Patient has received at least **ONE** prior multiple myeloma therapy
      i. Used in combination with lenalidomide (Revlimid) and dexamethasone
   b. Patient has received at least **TWO** prior multiple myeloma therapies including lenalidomide (Revlimid) and a proteasome inhibitor
      i. Used in combination with pomalidomide (Pomalyst) and dexamethasone
2. Prescriber agrees to monitor liver functions periodically for signs of hepatotoxicity
Prior – Approval *Renewal* Requirements

**Age**  
18 years of age and older

**Diagnosis**

Patient must have the following:

- Multiple myeloma (MM)

**AND ALL** of the following:

1. Used in combination with dexamethasone and **ONE** of the following:
   a. lenalidomide (Revlimid)
   b. pomalidomide (Pomalyst)
2. Prescriber agrees to monitor liver functions periodically for signs of hepatotoxicity
3. **NO** disease progression or unacceptable toxicity

### Policy Guidelines

**Pre - PA Allowance**

None

**Prior - Approval Limits**

**Duration** 6 months

**Prior – Approval *Renewal* Limits**

**Duration** 12 months

### Rationale

**Summary**

Empliciti is a monoclonal antibody indicated for the treatment of multiple myeloma. Empliciti has been shown to cause hepatotoxicity and should be stopped if Grade 3 or higher of liver enzymes and therapy continued after return to baseline. Safety and effectiveness of Empliciti have not been established in pediatric patients (1).
Prior authorization is required to ensure the safe, clinically appropriate and cost-effective use of Empliciti while maintaining optimal therapeutic outcomes.

References

Policy History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2015</td>
<td>New Policy</td>
</tr>
<tr>
<td>March 2016</td>
<td>Annual review</td>
</tr>
<tr>
<td></td>
<td>Policy number changed from 5.04.73 to 5.21.73</td>
</tr>
<tr>
<td>June 2016</td>
<td>Annual review</td>
</tr>
<tr>
<td>September 2016</td>
<td>Annual review</td>
</tr>
<tr>
<td>June 2017</td>
<td>Annual editorial review</td>
</tr>
<tr>
<td>June 2018</td>
<td>Annual editorial review and reference update</td>
</tr>
<tr>
<td>November 2018</td>
<td>Addition of indication of multiple myeloma in combination with</td>
</tr>
<tr>
<td></td>
<td>pomalidomide and dexamethasone in patients who have received at least</td>
</tr>
<tr>
<td></td>
<td>two prior therapies including lenalidomide and a proteasome inhibitor</td>
</tr>
<tr>
<td>March 2019</td>
<td>Annual review</td>
</tr>
</tbody>
</table>

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 15, 2019 and is effective on April 1, 2019.